Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients

Journal of Clinical Oncology

Volumn 14, Issue 6, 1996, Pages 1885-1894

  Castiglione Gertsch, Monica ^a  

^a Intl Breast Cancer Stud Grp C   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE;

ADJUVANT THERAPY; ADULT; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0029947991     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.6.1885     Document Type: Article

References (20)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
2. Bonadonna G, Valagussa P, Zambetti M, et al: Milan adjuvant trials for stage I-II breast cancer, in Salmon SE (ed): Adjuvant Therapy of Cancer V. Orlando, FL, Grune & Stratton, 1987, pp 211-221
3. Levine MN, Gent M, Hryniuk WM, et al: A randomized trial comparing 12 weeks with 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol 8:1217-1225, 1990
4. Senn HJ, Jungi WF, Amgwerd R, et al: Swiss adjuvant trial (OSAKO 06/74) with chlorambucil, methotrexate, and 5-fluorouracil plus BCG in node-negative breast cancer patients: nine-year results. NCI Monogr 1:129-134, 1986
5. Henderson IC, Gelman RS, Harris JR, et al: Duration of therapy in adjuvant chemotherapy trials. NCI Monogr 1:95-98, 1986
6. Falkson HC, Gray R, Wolberg WH, et al: Adjuvant therapy of post-menopausal women with breast cancer - An ECOG phase III study. J Clin Oncol 8:599-607, 1989
7. Ludwig Breast Cancer Study Group; Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 319:677-683, 1988
8. Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320:491-496, 1989
9. Speer JF, Petrosky VE, Retsky MW, et al: A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res 44:4124-4130, 1984
10. Gompertz B: On the nature of the function expressive of the law of human mortality and on a new mode of determining the value of life contingencies. Phil Trans R Soc London 115:513-585, 1825
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Gelber RD, Zelen M: Planning and reporting clinical trials, in Calabresi P, Rosenberg SA, Schein P (eds): Medical Oncology: Basic Principles and Clinical Management of Cancer. New York, NY, Macmillan, 1985, pp 406-425
13. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
14. Hürny C, Bernhard J, Gelber RD, et al: Quality of life measures for patients receiving adjuvant therapy for breast cancer: An international trial. Eur J Cancer 28:118-124, 1992
15. Schumacher M, Bastert G, Bojar H, et al: Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. J Clin Oncol 12:2086-2093, 1994
16. Clahsen PC, van de Velde CJH, Welvaart K, et al: Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: A joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party study. J Clin Oncol 13:33-41, 1995
17. Dombernowsky P, Hansen PS, Mouridsen HT, et al: Randomized trial of adjuvant CMF + radiotherapy (RT) vs CMF alone vs tamoxifen (TAM) in pre- and menopausal stage II breast cancer. Ann Oncol 5:2, 1994 (suppl 8; abstr 04)
18. Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 2:171-175, 1987
19. Valagussa P, Tancini G, Bonadonna G: Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58:1411-1417, 1986
20. Plotkin D, Waugh WJ: Hypothesis: Discontinuous chemotherapy for advanced breast cancer. Am J Clin Oncol 6:375-379, 1983